A phase I/II clinical trial (NCT01027676), addressing the capacity of vorinostat to synergize and overcome resistance to the EGFR-TKI gefitinib in treated patients with advanced non-small-cell lung cancer (NSCLC), has demonstrated this combination to be feasible and well tolerated at the clinical regime of biweekly 400 mg/day vorinostat and daily doses of 250 mg gefitinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.